Since the previous review, there have been 24 recruits to the Cancer Institute: seven translational, eight basic scientists, and nine clinical. Table 7.5.1 shows recruitments to date. While NYUCI institutional funds were used to support the expense of these recruits CCSG funds were used to fund pilot projects in the laboratories of many of these recruits, and to fund new cores without which these recruitments would not have been possible (e.g. Genomics Facility and siRNA core). As mentioned in Section 6.0 NYUCI recruitment took place in three phases during the last funding period. The first phase focused on key recruits with significant cancer focus that would complement the existing community. Thus the recruitment of Drs. Bhardwaj and O'Neill extended existing excellence in immunology to include immunotherapy as well as adding melanoma to our CCSG disease based programs that already included Genitourinary and Breast Cancer. The Chair of the Department of Pathology, David Roth, MD, PhD, and Co-Program Leader of the Immunology Program loaned the Cancer Institute space for the early recruitments of Drs. Bhardwaj, Dynlacht and O'Neill. This year, Drs. Bhardwaj and Dynlacht have since moved into the Cancer Research Center and Dr. O'Neill to the Vaccine Facility. The second phase focused on increasing depth in the clinical program with specific investments in recruits that would expand clinical services and research capabilities. The Clinical Cancer Center opened July 2004, and recruitment for disease based, programmatically aligned clinicians (e.g. Novik, Axelrod, Tiersten, Chandra, Skinner and others) prior to its opening provided for an environment of multi-disciplinary clinical research and care from its inception. Currently the NYUCI has 12 Disease Management Groups. Finally, with the opening of the Smilow Research Center May 2006, the three research floors of the Cancer Research Center opened and the newest recruits arrived on campus (Dasgupta, Yamasaki, Cho, Krogsgaard, Trombetta). Developmental Funds were earmarked to recruit a Deputy Director for Clinical Research to build the clinical research enterprise and foster collaborations across research entities to translate laboratory findings in the clinic, to recruit a molecular epidemiologist to bridge research within various programs, and build a collaborative and interactive Epidemiology and Prevention Program. These priorities were based upon the initiatives of the Strategic Plan and the recommendations of the EAB. In 2005, William Carroll, MD was named the Deputy Director for the Cancer Institute, responsible for the clinical research enterprise. We were, however, unsuccessful in recruiting a Molecular Epidemiologist, and in 2005, Dr. Roy Shore, the Associate Director for Epidemiology and Prevention took a position in Japan, and recruitment efforts to fill this position became our highest priority. In early 2006, a candidate was in final negotiations, yet decided to stay at his institution. The CI is actively recruiting for both positions and is in preliminary negotiations with one of the final candidates for the Associate Director position;our plan is to have this position filled by the Site Visit.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016087-29
Application #
7843319
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-03-01
Budget End
2010-02-28
Support Year
29
Fiscal Year
2009
Total Cost
$403,724
Indirect Cost
Name
New York University
Department
Type
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10016
Puranik, Amrutesh S; Leaf, Irina A; Jensen, Mark A et al. (2018) Kidney-resident macrophages promote a proangiogenic environment in the normal and chronically ischemic mouse kidney. Sci Rep 8:13948
Saint Fleur-Lominy, Shella; Maus, Mate; Vaeth, Martin et al. (2018) STIM1 and STIM2 Mediate Cancer-Induced Inflammation in T Cell Acute Lymphoblastic Leukemia. Cell Rep 24:3045-3060.e5
Cui, Xin; Morales, Renee-Tyler Tan; Qian, Weiyi et al. (2018) Hacking macrophage-associated immunosuppression for regulating glioblastoma angiogenesis. Biomaterials 161:164-178
Weng, Mao-Wen; Lee, Hyun-Wook; Park, Sung-Hyun et al. (2018) Aldehydes are the predominant forces inducing DNA damage and inhibiting DNA repair in tobacco smoke carcinogenesis. Proc Natl Acad Sci U S A 115:E6152-E6161
Burgess, Hannah M; Pourchet, Aldo; Hajdu, Cristina H et al. (2018) Targeting Poxvirus Decapping Enzymes and mRNA Decay to Generate an Effective Oncolytic Virus. Mol Ther Oncolytics 8:71-81
Wong, Serre-Yu; Coffre, Maryaline; Ramanan, Deepshika et al. (2018) B Cell Defects Observed in Nod2 Knockout Mice Are a Consequence of a Dock2 Mutation Frequently Found in Inbred Strains. J Immunol 201:1442-1451
Handler, Jesse; Cullis, Jane; Avanzi, Antonina et al. (2018) Pre-neoplastic pancreas cells enter a partially mesenchymal state following transient TGF-? exposure. Oncogene 37:4334-4342
Diamond, Julie M; Vanpouille-Box, Claire; Spada, Sheila et al. (2018) Exosomes Shuttle TREX1-Sensitive IFN-Stimulatory dsDNA from Irradiated Cancer Cells to DCs. Cancer Immunol Res 6:910-920
Fan, Xiaozhou; Peters, Brandilyn A; Jacobs, Eric J et al. (2018) Drinking alcohol is associated with variation in the human oral microbiome in a large study of American adults. Microbiome 6:59
Chen, Danqi; Fang, Lei; Mei, Shenglin et al. (2018) Erratum: ""Regulation of Chromatin Assembly and Cell Transformation by Formaldehyde Exposure in Human Cells"". Environ Health Perspect 126:019001

Showing the most recent 10 out of 1170 publications